MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings
Open Access
- 8 February 2010
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 45 (9) , 1449-1456
Abstract
Mycophenolate mofetil (MMF) in combination with CsA seems to lead to earlier post transplant hematological recovery and less mucositis than MTX, with a similar incidence of GVHD. In this study we analyzed the post transplant outcomes of two cohorts of patients who underwent an HLA-identical sibling reduced intensity conditioning transplantation (allo-RIC) with GVHD prophylaxis consisting of CsA in combination with either MMF or a short course of MTX. We included 145 consecutive allo-RIC transplants performed between April 2000 and August 2007. The median follow-up for survivors was 41 months (4–105 months). The study group included 91 males. Median age was 55 years (range 18–71 years). Diagnoses included myeloid (n=65) and lymphoid (n=80) malignancies. GVHD prophylaxis consisted of CsA/MMF in 52 and CsA/MTX in 93 patients. The conditioning regimen was based on fludarabine in combination with BU (n=59) or melphalan (n=86). The occurrence of grade 2–4 mucositis was higher in the CsA/MTX group than in the CsA/MMF group (57 vs 23%, P=0.001). The cumulative incidence of acute and chronic GVHD was similar, 48 vs 50% and 71 vs 68%, respectively (P>0.7). The 2-year relapse and OS were similar in the CsA/MTX and CsA/MMF groups (29 vs 21%, P=0.3 and 52 vs 51%, P=0.7, respectively). Our results support further prospective studies comparing the use of the CsA/MMF combination with CsA/MTX as GVHD prophylaxis in HLA-identical sibling donor allo-RIC recipients.Keywords
This publication has 34 references indexed in Scilit:
- Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation, 2007
- Conventional versus reduced‐intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignanciesEuropean Journal of Haematology, 2005
- Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results from the Spanish multicenter prospective trialBone Marrow Transplantation, 2004
- Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioningBone Marrow Transplantation, 2003
- Allogeneic peripheral blood stem cell transplantation with reduced‐intensity conditioning: results of a prospective multicentre studyBritish Journal of Haematology, 2001
- Enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapyBone Marrow Transplantation, 2001
- MYCOPHENOLATE MOFETIL AND CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC BLOOD STEM CELL TRANSPLANTATIONTransplantation, 1999
- Preliminary Risk-Benefit Assessment of Mycophenolate Mofetil in Transplant RejectionDrug Safety, 1997
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958